OTC: ODTC - Odonate, Inc.

Yield per half year: -63.34%
Dividend yield: 0.00%
Sector: Financials

Share chart Odonate, Inc.


About Odonate, Inc.

Odonate, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was formerly known as Odonate Therapeutics, Inc. and changed its name to Odonate, Inc. in March 2023. The company was founded in 2013 and is based in New York, New York.


IPO date 2017-12-07
ISIN US6760791060
Industry Capital Markets
Sector Financials
Валюта usd
Валюта отчета usd
Сайт https://www.odonate.com
Цена ао 50000
Change price per 3 month: -71.6% (176040)
Change price per half year: -63.34% (136400)
Change price per year: +1 328.57% (3500)
Change price per 3 year: +3 968 153.97% (1.26)
Change price per 5 year: +244 398.78% (20.45)
Change price per year to date: -63.45% (136800)

Underestimation

Title Value Grade
P/S 0 0
P/BV 398.17 1
P/E 5877.13 1
EV/EBITDA -54036.12 0
Total: 0.75

Efficiency

Title Value Grade
ROA, % 6.63 2
ROE, % 6.77 2
Total: 0.6667

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -2.89 10
Total: 8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % -108.27 0
Yield EPS, % -164.78 0
Total: 0



Head Job title Payment Year of birth
Mr. Kevin C. Tang Chairman & CEO 1 1967 (58 years)
Mr. Michael S. Hearne CFO & Principal Accounting Officer 251.23k 1963 (62 years)
Mr. Ryan Cole Senior Vice President of Operations N/A
Dr. Steven S. Pfeiffer Ph.D. Senior Vice President of Technical Operations N/A 1976 (49 years)
Mr. Thomas Wei Chief Scientific Officer N/A 1976 (49 years)

Address: United States, New York. NY, 3 East 28th Street - open in Google maps, open in Yandex maps
Website: https://www.odonate.com